{{Rsnum
|rsid=2676527
|Gene=RAPGEF4
|Chromosome=2
|position=172882984
|Orientation=minus
|GMAF=0.02801
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
|Gene_s=RAPGEF4
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 92.9 | 7.1 | 0.0
| HCB | 99.3 | 0.7 | 0.0
| JPT | 92.1 | 7.9 | 0.0
| YRI | 70.7 | 27.9 | 1.4
| ASW | 87.7 | 10.5 | 1.8
| CHB | 99.3 | 0.7 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 99.0 | 1.0 | 0.0
| LWK | 85.3 | 14.7 | 0.0
| MEX | 98.3 | 1.7 | 0.0
| MKK | 89.0 | 10.3 | 0.6
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2676527
|Name_s=
|Gene_s=RAPGEF4
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: C, MAF= 0.03, combined P value= 4.64E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470242
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2676527
|overall_frequency_n=121
|overall_frequency_d=126
|overall_frequency=0.960317
|n_genomes=54
|n_genomes_annotated=0
|n_haplomes=103
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}
{{on chip | Affy GenomeWide 6}}